| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
34 |
| Employees |
2,400 |
| Revenues (TTM) (Millions $) |
619 |
| Net Income (TTM) (Millions $) |
37 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
65 |
Business Description
Cambrex Corporation is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs) for the biopharmaceutical industry. The company was founded in 1981 and is headquartered in East Rutherford, New Jersey, United States.
Cambrex's services cover a wide range of areas, including custom development and manufacture of APIs, analytical development and testing, formulation development, and finished dosage form manufacturing. The company works with small to mid-sized biopharmaceutical companies, as well as multinational pharmaceutical corporations.
The company operates in three business segments: Small Molecules, Biologics, and Drug Product. The Small Molecules segment provides custom development and manufacturing services for APIs that are used in a variety of therapeutic areas, including oncology, anti-viral, anti-inflammatory, and cardiovascular. The Biologics segment specializes in the development and manufacture of biologic APIs, such as monoclonal antibodies, recombinant proteins, and vaccines. The Drug Product segment provides finished dosage form manufacturing, including capsule filling and tablet compression.
Cambrex has a strong global presence and operates a network of facilities in the United States, Europe, and Asia-Pacific. Its facilities are equipped with advanced technology and equipment, enabling the company to provide high-quality services to its customers. The company has a robust quality management system and is certified by regulatory agencies such as the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA).
The company has a strong track record of growth, driven by its focus on providing high-quality services to its customers. Cambrex has made strategic acquisitions, such as Halo Pharma in 2018, to expand its capabilities and strengthen its position in the CDMO industry. It has also made significant investments in research and development to develop innovative solutions for its customers.
In summary, Cambrex Corporation is a leading global CDMO that provides custom development and manufacturing services for APIs and finished dosage forms to the biopharmaceutical industry. With its strong global presence, advanced technology and equipment, and robust quality management system, Cambrex is well-positioned for further growth and success in the future.
Company Address: ONE MEADOWLANDS PLAZA EAST RUTHERFORD 7073 NEW JERSEY
Company Phone Number: 804-3000 Stock Exchange / Ticker: CBM
|
%